CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research
Edgewater Wireless Reports Fiscal 2026 Year-End Results and Highlights Growing Semiconductor Execution and Industry Validation
Silver Hammer and Stroud Resources Announce Updated Mineral Resource Estimate for the Santo Domingo Silver-Gold Project, Mexico
